Patents by Inventor Brooks M. Boyd
Brooks M. Boyd has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11673852Abstract: Metabolism-resistant fenfluramine analogs are provided. The subject fenfluramine analogs find use in the treatment of a variety of diseases. For example, methods of treating epilepsy by administering a fenfluramine analog to a subject in need thereof are provided. Also provided are methods of suppressing appetite in a subject in need thereof. Pharmaceutical compositions for use in practicing the subject methods are also provided.Type: GrantFiled: April 5, 2022Date of Patent: June 13, 2023Assignee: ZOGENIX INTERNATIONAL LIMITEDInventors: Stephen J. Farr, Brooks M. Boyd
-
Publication number: 20230093150Abstract: Disclosed herein are methods of improving cognitive function in a patient as measured by, for example, improvement in score on a validated scale that measures cognitive function, such as the Behavior Rating Inventory of Executive Function (BRIEF), by administering the test to a patient and obtaining a pre-treatment test score, treating the patient with fenfluramine or its pharmaceutically acceptable salt, and after treatment, re-administering the test of cognitive function to the patient and obtaining a post-treatment score, to allow observation of an improvement in the test score. In some embodiments, the patient is also being treated for the symptoms of epilepsy.Type: ApplicationFiled: May 5, 2022Publication date: March 23, 2023Applicant: ZOGENIX INTERNATIONAL LIMITEDInventors: Glenn MORRISON, Arnold GAMMAITONI, Brooks M. BOYD
-
Publication number: 20230076320Abstract: Functional analogs of fenfluramine are provided. Methods of treating Dravet syndrome with (?) norfenfluramine are disclosed. Pharmaceutical compositions for use in practicing the subject methods are also provided.Type: ApplicationFiled: August 31, 2022Publication date: March 9, 2023Applicant: ZOGENIX INTERNATIONAL LIMITEDInventors: Parthena MARTIN, Brooks M. BOYD, Arnold GAMMAITONI, Bradley S. GALER, Gail FARFEL
-
Publication number: 20220370381Abstract: Functional analogs of fenfluramine are provided. The subject fenfluramine functional analogs find use in the treatment of a variety of diseases. For example, methods of treating epilepsy by administering a fenfluramine analog to a subject in need thereof are provided. Also provided are methods of treating a neurodegenerative disease in a subject in need thereof. Pharmaceutical compositions for use in practicing the subject methods are also provided.Type: ApplicationFiled: June 17, 2022Publication date: November 24, 2022Applicant: ZOGENIX INTERNATIONAL LIMITEDInventors: Parthena MARTIN, Brooks M. BOYD, Arnold GAMMAITONI, Bradley S. Galer, Gail FARFEL
-
Patent number: 11458111Abstract: A method of treating symptoms of a subtype of epilepsy, e.g., Dravet syndrome, in a patient diagnosed with a subtype of epilepsy, by administering to the patient an effective dose of a fenfluramine formulation in combination with a ketogenic diet over a period of time sufficient to reduce or completely eliminate seizures in the patient. Also provided are compositions and kits finding use in practicing embodiments of the methods.Type: GrantFiled: May 4, 2020Date of Patent: October 4, 2022Assignee: ZOGENIX INTERNATIONAL LIMITEDInventors: Khawla Abu-Izza, David Hickman, Glenn Morrison, Brooks M. Boyd
-
Publication number: 20220289663Abstract: Metabolism-resistant fenfluramine analogs are provided. The subject fenfluramine analogs find use in the treatment of a variety of diseases. For example, methods of treating epilepsy by administering a fenfluramine analog to a subject in need thereof are provided. Also provided are methods of suppressing appetite in a subject in need thereof. Pharmaceutical compositions for use in practicing the subject methods are also provided.Type: ApplicationFiled: April 5, 2022Publication date: September 15, 2022Applicant: ZOGENIX INTERNATIONAL LIMITEDInventors: Stephen J. FARR, Brooks M. BOYD
-
Patent number: 11325882Abstract: Metabolism-resistant fenfluramine analogs are provided. The subject fenfluramine analogs find use in the treatment of a variety of diseases. For example, methods of treating epilepsy by administering a fenfluramine analog to a subject in need thereof are provided. Also provided are methods of suppressing appetite in a subject in need thereof. Pharmaceutical compositions for use in practicing the subject methods are also provided.Type: GrantFiled: May 8, 2020Date of Patent: May 10, 2022Assignee: ZOGENIX INTERNATIONAL LIMITEDInventors: Stephen J. Farr, Brooks M. Boyd
-
Publication number: 20210113495Abstract: Provided herein are methods of identifying a patient population as candidates for effective treatment of symptoms of epilepsy or epileptic encephalopathy with fenfluramine or a pharmaceutically acceptable salt thereof, by pre-selecting patients diagnosed with epilepsy or epileptic encephalopathy, assessing the pre-selected patients for being at risk of or exhibiting symptoms of pulmonary hypertension, treating and re-assessing the selected and treated patients for pulmonary hypertension, and identifying treated and re-assessed patients not exhibiting pulmonary hypertension as candidates for effective treatment of epilepsy or epileptic encephalopathy with fenfluramine or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 3, 2019Publication date: April 22, 2021Applicant: ZOGENIX INTERNATIONAL LIMITEDInventors: Brooks M. BOYD, Gail FARFEL
-
Publication number: 20200331844Abstract: Metabolism-resistant fenfluramine analogs are provided. The subject fenfluramine analogs find use in the treatment of a variety of diseases. For example, methods of treating epilepsy by administering a fenfluramine analog to a subject in need thereof are provided. Also provided are methods of suppressing appetite in a subject in need thereof. Pharmaceutical compositions for use in practicing the subject methods are also provided.Type: ApplicationFiled: May 8, 2020Publication date: October 22, 2020Applicant: ZOGENIX INTERNATIONAL LIMITEDInventors: Stephen J. FARR, Brooks M. BOYD
-
Publication number: 20200306210Abstract: Disclosed herein are methods of improving cognitive function in a patient as measured by, for example, improvement in score on a validated scale that measures cognitive function, such as the Behavior Rating Inventory of Executive Function (BRIEF), by administering the test to a patient and obtaining a pre-treatment test score, treating the patient with fenfluramine or its pharmaceutically acceptable salt, and after treatment, re-administering the test of cognitive function to the patient and obtaining a post-treatment score, to allow observation of an improvement in the test score. In some embodiments, the patient is also being treated for the symptoms of epilepsy.Type: ApplicationFiled: October 8, 2019Publication date: October 1, 2020Applicant: ZOGENIX INTERNATIONAL LIMITEDInventors: Glenn MORRISON, Arnold GAMMAITONI, Brooks M. BOYD
-
Publication number: 20200297665Abstract: Functional analogs of fenfluramine are provided. The subject fenfluramine functional analogs find use in the treatment of a variety of diseases. For example, methods of treating epilepsy by administering a fenfluramine analog to a subject in need thereof are provided. Also provided are methods of treating a neurodegenerative disease in a subject in need thereof. Pharmaceutical compositions for use in practicing the subject methods are also provided.Type: ApplicationFiled: May 22, 2020Publication date: September 24, 2020Applicant: ZOGENIX INTERNATIONAL LIMITEDInventors: Parthena MARTIN, Brooks M. BOYD, Arnold GAMMAITONI, Bradley S. Galer, Gail FARFEL
-
Publication number: 20200276136Abstract: Provided herein is a method of treating a selected patient population, wherein the patient population is selected based on a determination that the patients have previously been non-responsive when treated with cannabidiol. In some embodiments, the method comprises selecting the patient based on a previously failed treatment with cannabidiol, based on lack of efficacy or tolerability. Pharmaceutical compositions and formulations for use in practicing the subject methods are also provided. The method comprises identifying a population of patients diagnosed with Dravet syndrome who were found previously to have been non-responsive when treated with cannabidiol.Type: ApplicationFiled: May 11, 2020Publication date: September 3, 2020Applicant: ZOGENIX INTERNATIONAL LIMITEDInventors: Bradley S. GALER, Glenn MORRISON, Brooks M. BOYD
-
Publication number: 20200261380Abstract: A method of treating symptoms of a subtype of epilepsy, e.g., Dravet syndrome, in a patient diagnosed with a subtype of epilepsy, by administering to the patient an effective dose of a fenfluramine formulation in combination with a ketogenic diet over a period of time sufficient to reduce or completely eliminate seizures in the patient. Also provided are compositions and kits finding use in practicing embodiments of the methods.Type: ApplicationFiled: May 4, 2020Publication date: August 20, 2020Inventors: Khawla ABU-IZZA, David HICKMAN, Glenn MORRISON, Brooks M. BOYD
-
Patent number: 10689324Abstract: Metabolism-resistant fenfluramine analogs are provided. The subject fenfluramine analogs find use in the treatment of a variety of diseases. For example, methods of treating epilepsy by administering a fenfluramine analog to a subject in need thereof are provided. Also provided are methods of suppressing appetite in a subject in need thereof. Pharmaceutical compositions for use in practicing the subject methods are also provided.Type: GrantFiled: December 20, 2016Date of Patent: June 23, 2020Assignee: ZOGENIX INTERNATIONAL LIMITEDInventors: Stephan J. Farr, Brooks M. Boyd
-
Patent number: 10682317Abstract: A method of treating symptoms of a subtype of epilepsy, e.g., Dravet syndrome, in a patient diagnosed with a subtype of epilepsy, by administering to the patient an effective dose of a fenfluramine formulation in combination with a ketogenic diet over a period of time sufficient to reduce or completely eliminate seizures in the patient. Also provided are compositions and kits finding use in practicing embodiments of the methods.Type: GrantFiled: September 24, 2018Date of Patent: June 16, 2020Assignee: ZOGENIX INTERNATIONAL LIMITEDInventors: Khawla Abu-Izza, David Hickman, Glenn Morrison, Brooks M. Boyd
-
Publication number: 20190247333Abstract: A method of reducing convulsive seizure frequency in a human patient diagnosed with Dravet syndrome, comprising administering to the patient a therapeutically effective dose of fenfluramine or a pharmaceutically acceptable salt, base, acid or amine thereof, and repeating the administering over a period of days until the patient exhibits a significant reduction (e.g., 40% or greater) from baseline in convulsive seizure frequency. In some embodiments of the method, convulsive seizures are completely eliminated for 10 days or more, 20 days or more, 30 days or more, 50 days or more, 100 days or more.Type: ApplicationFiled: February 15, 2019Publication date: August 15, 2019Applicant: ZOGENIX INTERNATIONAL LIMITEDInventors: Gail FARFEL, Michael LOCK, Brooks M. BOYD
-
Publication number: 20190125697Abstract: A method of reducing convulsive seizure frequency in a human patient diagnosed with Dravet syndrome, comprising administering to the patient a therapeutically effective dose of fenfluramine or a pharmaceutically acceptable salt, base, acid or amine thereof, and repeating the administering over a period of days until the patient exhibits a significant reduction (e.g., 40% or greater) from baseline in convulsive seizure frequency. In some embodiments of the method, convulsive seizures are completely eliminated for 10 days or more, 20 days or more, 30 days or more, 50 days or more, 100 days or more.Type: ApplicationFiled: September 24, 2018Publication date: May 2, 2019Applicant: ZOGENIX INTERNATIONAL LIMITEDInventors: Gail FARFEL, Michael LOCK, Brooks M. BOYD
-
Publication number: 20190091173Abstract: A method of increasing an average time between seizures in a human patient diagnosed with Dravet syndrome, comprising administering to the patient a therapeutically effective dose of fenfluramine or a pharmaceutically acceptable salt, base, acid or amine thereof, and repeating the administering over a period of days until the patient exhibits an increase from baseline in average time between convulsive seizures of 6 hours, days weeks or more.Type: ApplicationFiled: September 24, 2018Publication date: March 28, 2019Applicant: ZOGENIX INTERNATIONAL LIMITEDInventors: Gail FARFEL, Michael LOCK, Brooks M. BOYD
-
Publication number: 20190091177Abstract: Provided herein is a method of treating a selected patient population, wherein the patient population is selected based on a determination that the patients have previously been non-responsive when treated with stiripentol. In some embodiments, the method comprises selecting the patient based on a previously failed treatment with stiripentol, based on lack of efficacy or tolerability. Pharmaceutical compositions and formulations for use in practicing the subject methods are also provided. The method comprises identifying a population of patients diagnosed with Dravet syndrome who were found previously to have been non-responsive when treated with stiripentol.Type: ApplicationFiled: September 24, 2018Publication date: March 28, 2019Applicant: ZOGENIX INTERNATIONAL LIMITEDInventors: Bradley S. GALER, Glenn MORRISON, Brooks M. BOYD
-
Publication number: 20190091179Abstract: Disclosed herein are methods of improving cognitive function in a patient as measured by, for example, improvement in score on a validated scale that measures cognitive function, such as the Behavior Rating Inventory of Executive Function (BRIEF), by administering the test to a patient and obtaining a pre-treatment test score, treating the patient with fenfluramine or its pharmaceutically acceptable salt, and after treatment, re-administering the test of cognitive function to the patient and obtaining a post-treatment score, to allow observation of an improvement in the test score. In some embodiments, the patient is also being treated for the symptoms of epilepsy.Type: ApplicationFiled: September 24, 2018Publication date: March 28, 2019Applicant: ZOGENIX INTERNATIONAL LIMITEDInventors: Glenn MORRISON, Arnold GAMMAITONI, Brooks M. BOYD